Otsuka announces simultaneous regulatory approvals by U.S. FDA and Health Canada of INQOVI?, an oral hypomethylating agent (HMA) therapy for MDS and CMML
- First orally administered hypomethylating agent approved by the FDA and Health Canada
- An option for patients with MDS and CMML to potentially reduce the number of office visits and to take their medication from the convenience and comfort of their homes